At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05844644Phase 2RecruitingUpdate OverdueUpdated 23mo ago · Completion was 19mo agoAn Open Label Study Evaluating the Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes
In Brief
A Phase 2 clinical trial evaluating Release for Type 2 Diabetes and 3 related conditions. Currently recruiting, targeting 100 participants across 2 sites.
Signals
Detailed Summary
The objective of this study is to investigate the efficacy and safety of the GOLO for Life® Plan (G4LP) and Release supplementation on glycemic control and weight in overweight and obese adults with Prediabetes or Type 2 Diabetes. The change in glycemic control from baseline at Days 90 and 180 following the G4LP and supplementation with Release will be assessed. Additionally, the safety and tolerability of the G4LP and Release supplementation will be measured by the occurrence of and/or changes in pre-emergent and post-emergent adverse events (AEs).
Study Details
Timeline
Interventions
One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.